Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer
- PMID: 28399386
- PMCID: PMC5791834
- DOI: 10.1200/JOP.2017.022772
Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer
Comment on
-
Biomarkers for Selection of Therapy for Adenocarcinoma of the Lung.J Oncol Pract. 2017 Apr;13(4):221-227. doi: 10.1200/JOP.2016.019182. J Oncol Pract. 2017. PMID: 28399384 Review.
References
-
- Bernicker EH, Miller RA, Cagle PT. Biomarkers for selection of therapy for adenocarcinoma of the lung. J Oncol Pract 13:221-228, 2017. - PubMed
-
- Imyanitov EN, Demidova IA, Gordiev MG, et al. Distribution of EGFR mutations in 10,607 Russian patients with lung cancer. Mol Diagn Ther. 2016;20:401–406. - PubMed
-
- Alì G, Proietti A, Pelliccioni S, et al. ALK rearrangement in a large series of consecutive non-small cell lung cancers: Comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment. Arch Pathol Lab Med. 2014;138:1449–1458. - PubMed
-
- Grilley-Olson JE, Hayes DN, Moore DT, et al. Validation of interobserver agreement in lung cancer assessment: Hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: The 2004 World Health Organization classification and therapeutically relevant subsets. Arch Pathol Lab Med. 2013;137:32–40. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
